Impact of COVID-19 pandemic on design and conduct of clinical                trials: developing best practices based on lessons learned for risk and change management

Marina A. Malikova

doi:10.18203/2349-3259.ijct20210148

Authors

Marina A. Malikova Department of Surgery, Boston University School of Medicine, Boston Medical Center, Boston, MA http://orcid.org/0000-0003-1370-187X

DOI:

https://doi.org/10.18203/2349-3259.ijct20210148

Keywords:

Impact of COVID-19 pandemic on clinical trials conduct, Change and risk management, Regulatory updates, Safety monitoring, Data integrity, Patient centricity

Abstract

The coronavirus disease 2019 (COVID- 19) pandemic is disrupting clinical research in most of the world. We have seen an immediate impact on clinical trials due to challenges coming from the COVID-19 travel bans, hospitals/clinics’ visitation restrictions, social distancing precautions and shifting operations to work remotely on a short notice. These factors have translated into the issues challenging clinical trials such as operations, milestones, budgets, data integrity, etc. Given the complex risk/benefit considerations associated with each specific clinical trial, there is no single solution to manage the risks in clinical trials conduct due to COVID-19. Each trial is unique with respect to patient population, study drug mechanism of action, concomitant medications, and geographic location needs. It is important to continue to engage the networks and communities to push forward with creative risk mitigation and develop solutions during this challenging time. Risk assessment should be a continuous and living process as the situation evolves over the coming weeks to months. Routine and ongoing cross checks with study teams are already proving to maintain alignment on key timelines, critical risk points and other study specific challenges as we are moving towards de-centralized settings in the conduct of clinical trials. We have analyzed lessons learned and attempted to develop best practices to mitigate risks and adjust clinical research operations during this unprecedented time.

Metrics

Metrics Loading ...

Author Biography

Marina A. Malikova, Department of Surgery, Boston University School of Medicine, Boston Medical Center, Boston, MA

Assistant Professor of Surgery, Department of Surgery

References

Secretary of Health and Human Services Alex M. Azar II. Determination that a public health emergency exists. 2020 (renewed April 21, 2020). Available at: https://www.phe.gov/emergency/ news/healthactions/phe/Pages/default.aspx. Accessed on 03 August, 2020.

Proclamation on declaring a national emergency concerning the novel coronavirus disease (COVID-19) outbreak. 2020. Available at: https://www. whitehouse.gov/presidential-actions/proclamation-declaring-nationalemergency-concerning-novel-coronavirus-disease-covid-19-outbreak/. Accessed on 03 August, 2020.

WHO Director-General's statement on IHR emergency committee on novel coronavirus (2019-nCoV). Public health emergency of international concern declared by WHO. 2020. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov). Accessed on 03 August, 2020.

WHO Director-General's opening remarks at the media briefing on COVID-19. 2020. Available at: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed on 03 August, 2020.

Weekly update on COVID-19th. 2020. Available at: https://www.who.int/publications/m/item. Accessed on 03 August, 2020.

Timeline of WHO’s response to COVID-19. 2020. https://www.who.int/news-room/detail/29-06-2020-covidtimeline. Accessed on 03 August, 2020.

FDA Guidance for industry, investigators, and Institutional Review Boards on conduct of clinical trials of medical products during COVID-19 public health emergency. 2020. (revised on July, 2nd of 2020)

Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/fda-guidance-conduct-clinical-trials-medical-products-during-covid-19-public-health-emergency. Accessed on 03 August, 2020.

Considerations to support clinical trial monitoring oversight during COVID-19 by Association of Clinical Research Organizations. 2020. Available at: https://www.acrohealth.org/wp-content/uploads/ 2020/03/ACRO-Statement-on-Monitoring-Oversight-FINAL-3.13.20.pdf. Accessed on 03 August, 2020.

Francis G. and Wydenbach K. MHRA advice for management of clinical trials in relation to coronavirus. 2020. Available at: https://mhrain spectorate.blog.gov.uk/2020/03/12/advice-for-management-of-clinical-trials-in-relation-to-coronavirus/. Accessed on 03 August, 2020.

EMA Guidance on the management of clinical trials during the COVID-19 (Coronavirus) pandemic. Version 3. 2020. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/guidanceclinicaltrials_covid19_en.pdf. Accessed on 03 August, 2020.

FDA Guidance for IRBs and clinical investigators: Institutional Review Board (IRB) review of individual patient expanded access requests for investigational drugs and biological products during the COVID-19 public health emergency. 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/institutional-review-board-irb-review-individual-patient-expanded-access-requests-investigational. Accessed on 03 August, 2020.

Marra C, Chen JL, Coravos A et al. Quantifying the use of connected digital products in clinical research. npj Digit. Med. 2020;3(5).

Clarke I. Data shows a majority of patients remain interested in clinical trials during the coronavirus pandemic. 2020. Available at: https://www.subjectwell.com/news/data-shows-a-majority-of-patients-remain-interested-in-clinical-trials-during-the-coronavirus-pandemic/. Accessed on 03 August, 2020.

FDA updates COVID-19 clinical trials guidance to address serious adverse events. Available at: https://www.raps.org/news-and-articles/news-articles/2020/5/fda-updates-covid-19-clinical-trials-guidance-to-a. Accessed on 03 August, 2020.

FDA Guidance to industry: statistical considerations for clinical trials during the COVID-19 public health emergency guidance for industry. 2020. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-considerations-clinical-trials-during-covid-19-public-health-emergency-guidance-industry. Accessed on 03 August, 2020.

Commissioner of Food and Drug Administration Stephen M. Hahn. FDA Statement.

Coronavirus (COVID-19) Update: FDA prepares for resumption of domestic inspections with new risk assessment system. 2020. Available at: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-prepares-resumption-domestic-inspections-new-risk-assessment-system. Accessed on 03 August, 2020.

Commissioner of Food and Drug Administration Stephen M. Hahn. FDA Statement. Coronavirus disease 2019 (COVID-19) update: Foreign inspections. 2020. Available at: https://www.fda.gov /news-events/press-announcements/coronavirus-disease-2019-covid-19-update-foreign-inspections. Accessed on 03 August, 2020.

Integrated Addendum to ICH E6 (R1): Guideline for Good Clinical Practice E6 (R2). Available at: https://www.ich.org/fileadmin/Public_Web.../E6/E6_R2__Step_4_2016_1109.pdf. Accessed on 03 August, 2020.